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We report the identification of six patients with 3q29 microdeletion syndrome. The clinical phenotype is variable
despite an almost identical deletion size. The phenotype includes mild-to-moderate mental retardation, with only
slightly dysmorphic facial features that are similar in most patients: a long and narrow face, short philtrum, and
high nasal bridge. Autism, gait ataxia, chest-wall deformity, and long and tapering fingers were noted in at least
two of six patients. Additional features—including microcephaly, cleft lip and palate, horseshoe kidney and hy-
pospadias, ligamentous laxity, recurrent middle ear infections, and abnormal pigmentation—were observed, but
each feature was only found once, in a single patient. The microdeletion is ∼1.5 Mb in length, with molecular
boundaries mapping within the same or adjacent bacterial artificial chromosome (BAC) clones at either end of the
deletion in all patients. The deletion encompasses 22 genes, including PAK2 and DLG1, which are autosomal
homologues of two known X-linked mental retardation genes, PAK3 and DLG3. The presence of two nearly
identical low-copy repeat sequences in BAC clones on each side of the deletion breakpoint suggests that nonallelic
homologous recombination is the likely mechanism of disease causation in this syndrome.
The history of detecting microdeletion syndromes started
with the recognition of discrete syndromic phenotypes
associated with mental retardation, such as Prader-Willi,
Miller-Dieker, Angelman, and Williams syndromes. Pa-
tients with similar phenotypes were then found to have
similar submicroscopic deletions, in discrete genomic
regions, that then defined the condition (Ledbetter et al.
1981; Schwartz et al. 1988; Knoll et al. 1989; Ewart et
al. 1993).
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In 1995, Flint et al. developed a strategy to screen for
the abnormal inheritance of some subtelomeric DNA
polymorphisms in individuals who had mental retarda-
tion alone and no associated clinical syndrome (Flint et
al. 1995). Initially, 3 of 99 patients each had a single
deletion at one of the telomeres. Since then, the technology
has been developed to provide screening of all telomeres
as a clinical service for suitably selected patients with men-
tal retardation and dysmorphic features. The range of
diagnostic yield is ∼6%–11% (Knight et al. 1999; Sla-
votinek et al. 1999; Flint and Knight 2003; Koolen et al.
2004). The frequency of specific chromosome submicro-
scopic deletions or duplications reported in the literature
varies from single case reports to 150 cases reported (De
Vries et al. 2003). Conditions such as 1p36 or 2q37.3
microdeletions have been reported frequently, and these
conditions now assume the status of recognizable syn-
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dromes, since common clinical features have emerged
through the collection of patients with the same deletion
(Shapira et al. 1997; Heilstedt et al. 2003; Aldred et al.
2004). However, several of the subtelomeric deletions
have been reported only rarely to date, and the delineation
of the associated clinical phenotype is therefore much
more difficult.
We report here the identification of six patients with
a 3q29 microdeletion. In five patients, the deletion arose
de novo, and, for one patient, the parental origin could
not be determined. The clinical phenotype is described
in all six patients and is compared with that of a single
case that was reported by Rossi et al. (2001). The mo-
lecular boundaries of the recurrent 1.5-Mb deletion are
defined, and nonallelic homologous recombination is
proposed as a mechanism of deletion formation in these
patients.
Table 1 summarizes the clinical features of the six
patients presented here and includes the few clinical de-
tails available on the patient analyzed in the study by
Rossi et al. (2001). Figure 1 illustrates the patients’ facial
features and hands. To summarize, this condition is not
associated with any antenatal abnormalities, and the
birth history was uneventful in all patients. Birth mea-
surements were within the normal range, although mi-
crocephaly was noted in patient 6. The level of devel-
opmental delay often was not fully recognized until after
the 1st year of life, except in patient 6, in whom failure
to thrive was noted at 5 mo of age. Growth parameters
in all patients were at or below the 50th percentile but
remained in the normal range. Speech delay was a par-
ticular feature, and all children needed special educa-
tional provision because of more general intellectual dif-
ficulties, although one child was in a mainstream school
with substituted lessons in a specialist learning support
unit. Autism was a feature of the behavior of two of the
patients. Patient 1’s behavior was obsessive and repet-
itive and met the ICD-10 (International Classification of
Diseases, World Health Organization) diagnostic criteria
for autism spectrum disorders; patient 3 presented at 3
years of age with moderate-to-severe cognitive learning
difficulties with autistic traits but was not diagnosed as
having a recognized form of autism. His psychological
presentation was complex at that stage and remained
so. The dysmorphology in the children is variable and
not striking, but there are some facial similarities, and
each child also has certain unique features. Generally,
the face is long and narrow, especially in patients 2 and
4. The philtrum appears short in all patients, and a high
nasal bridge is present in patients 1, 2, 3, and 4. The
ears are generally large but well developed. The ad-
ditional features found in at least two individuals were
chest-wall deformity (pectus carinatum in one patient
and pectus excavatum in another) and long and tapering
fingers in two individuals, with fifth-finger clinodactyly
in one of them. One additional child was noted to have
fifth-finger brachydactyly, but X-ray assessment was not
performed. An ungainly, ataxic gait was described in two
patients, and, in patient 2, diagnoses of Angelman and
Rett syndromes were considered and excluded. Each of
the remaining features was identified only in a single pa-
tient: recurrent bilateral middle ear infections, requir-
ing grommets, adenoidectomy, and removal of a choles-
teatoma, in patient 2; ligamentous laxity in patient 3;
downslanting palpebral fissures, posteriorly rotated ears,
smooth philtrum, and prominent lower lip in patient 4;
left-sided unilateral cleft lip and palate and nail hypo-
plasia in patient 5; progressive microcephaly and ab-
normal skin pigmentation in patient 6; and horseshoe
kidney and hypospadias in the patient described by Rossi
et al. (2001).
Molecular cytogenetic results are summarized in table
2 and figure 2. The samples were collected from labo-
ratories in the United Kingdom and the Netherlands
(Nijmegen), and FISH was performed on interphase or
metaphase spreads, depending on the sample availabil-
ity. G-banding at the 550 band or at a higher level, FISH
probe preparation, and hybridization were performed us-
ing standard techniques. Parental samples were available
for patients 1–5, and all deletions had arisen de novo.
Patient 6 was adopted out of the birth family; thus, pa-
rental samples were unavailable for analysis. FISH anal-
ysis of patients 1 and 2 showed the presence of a terminal
deletion of 3q29 by use of 3qter probe pVYS223B from
the Totelvysion subtelomere screening kit (Vysis) on meta-
phase spreads. Deletions in patients 3 and 6 were initial-
ly suspected on high-resolution G-banding and were con-
firmed using the 3q subtelomeric probe CTC-196F4 from
the study by the National Institutes of Health and Insti-
tute of Molecular Medicine Collaboration (1996). In pa-
tient 5, the deletion was detected using probe 3qtel106
from the Cytocell subtelomere screening kit. Probes
pVYS223B, CTC-196F4, and 3qtel106 all map within
BAC clone RP5-1061C18 (fig. 2A). In patient 4, the de-
letion was detected using multiplex ligation-dependent
probe amplification (MLPA) (Koolen et al. 2004). The
3q29 deletion was not detectable with the older MLPA
MRC (Medical Research Council) Holland telomere kit,
PO19, which recognizes sequence in the nondeleted clone
RP11-496H1, but is identifiable only with the new kit,
PO36, which uses sequence within the BDH gene located
within the deleted clones RP13-616I3 and RP11-535N19
as a MLPA probe. To refine the deletion, 26 overlapping
BAC and PAC clones were identified using the then-avail-
able build 31 sequence (National Center for Biotechnol-
ogy Information [NCBI] Map Viewer). The human ge-
nomic clones from the RPCI-5, -11, and -13 BAC and
PAC libraries were obtained from the BACPAC Resources
Center. Slides were analyzed using a fluorescence micro-
scope (Leica DMRB), and images were recorded using
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Figure 1 Photographs of patient 1, at age 9 years, 11 mo; patient 2, at age 14 years; patient 3, at age 6 years, 7 mo; patient 4, at age
6 years; patient 5, at age 7 years, 11 mo; and patient 6, at age 8 years, 10 mo. Written consent to publish these photographs was obtained
from the parents of each child.
SmartCapture 2 software (Digital Scientific). Published
STS primers STS-R44803, SHGC-170324, D3S4248,
SHGC-34823, SHGC-149375, SHGC-10638, RH45269,
SHGC-146015, RH99161, D3S2320, and RH80465
were used to check the identity of the clones (fig. 2B). In
patients 1–4 and patient 6, the deletion endpoints were
refined to within a single BAC clone. The telomeric break-
point was within BAC clones RP11-594G13 and RP11-
496H1, and the centromeric breakpoint was within BAC
clones RP11-185G19 and RP11-480A16. For patient 5,
there was insufficient material available to define the cen-
tromeric breakpoint, but the telomeric breakpoint was
within BAC clone RP11-496H1, as for patient 2. The
centromeric breakpoint lay between BAC clones RP11-
171N2 and RP11-185G19 (table 2). At the telomeric
breakpoint, the two BAC clones that define the deletion
endpoint in the six patients overlap, and both contain
STSs RH45269 and SHGC-146015. Most of clone RP11-
594G13 is also contained within RP11-496H1, but clone
RP11-594G13 extends ∼60 kb further toward the cen-
tromere than RP11-496H1. On the basis of the resolution
of FISH, the breakpoints in each of the patients are likely
to be similar and to lie within 60–70 kb of each other.
The extent of the common microdeletion was deter-
mined using the finished sequence clones selected from
the contigs on NCBI build 35.1 (NCBI Map Viewer).
The microdeletion is estimated to be ∼1.5 Mb, and it
contains at least 22 transcripts, 5 of which are known
genes (PYT1A, PAK2 [MIM 605022], MFI2 [MIM
155750], DLG1 [MIM 601014], and BDH [MIM
603063]), 7 of which are incomplete cDNAs with two
or more documented cDNA sequences, and 10 of which
are hypothetical genes with no experimental evidence.
Since the deletion limits in the six patients were almost
identical, the finished genomic sequence on each side of
the deletion was investigated to determine whether any
region-specific low-copy repeats (LCRs) were present.
Nix analysis (HGMP-RC Nix Session Web site) of RP11-
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Table 2
Limits of Interstitial 3q29 Microdeletion in Six Unrelated Patients
CONTIG AND
BAC/PAC CLONEa
ACCESSION
NUMBER
PRESENCE OR ABSENCE
OF PROBE IN PATIENTb
1 2 3 4 5 6
NT_005612:
513G11 AC117469 P P P P P P
NT_005535:
279P10 AC125362 P P P P P P
NT_029928:
171N2 AC069513 P P P P NT P
352G9 AC124944 P P P P NT P
480A16 AC024937 P D D D NT D
185G19 AC139666 D D D D NT D
252K11 AC026308 D D D D D D
447L10 AC069257 D D D D NT D
106N22 AC083822 D D D D NT D
200I19 AC092933 D D D D NT D
133B21 AC023797 D D D D NT D
470E12 AC055725 D D D D NT D
607N15 AC127904 D D D D NT D
778E2 AC016949 D D D D D D
432D10 AC068302 D D D D NT D
114F20 AC092937 D D D D D D
RP5-1061C18 AL121981 D D D D D D
RP13-616I3 AC128709 D D D D D D
535N19 AC126183 D D D D D D
594G13 AC132008 P D P P D P
496H1 AC024560 P P P P P P
803P9 AC055764 P P P P P P
23M2 AC022621 P P P P P P
237O3 AC144530 P P P P NT P
643E20 AC135893 P P P P NT P
694O4 AC073135 P P P P NT P
NOTE.—All accession numbers listed in the table are from GenBank.
a Unless otherwise stated, the BAC or PAC clones used were from
the RP11 library.
b P p probe was present on both chromosome 3 homologues by
FISH; D p probe was deleted on one of the chromosome 3 homo-
logues; NT p probe was not tested, because of insufficient chromo-
somal material available from the patient.
496H1 (GenBank accession number AC024560) found
regions of sequence homology within BAC clones RP11-
480A16, RP11-352G9, and RP11-171N2. Two separate
LCR sequences, designated “repeat A” and “repeat B,”
were identified on each side of the deletion region (fig.
2C). By use of BLAT analysis (Human BLAT Search Web
site), repeat A was identified four times on chromosome
3, at positions 198832974–198852444, 197195390–
197215144, and 197150598–197155588 in one ori-
entation and at position 196868577–196884133 in the
opposite orientation. Each repeat was 197.5% homol-
ogous and was ∼19 kb, ∼19 kb, ∼5 kb, and ∼15 kb
long, respectively (fig. 2C). Repeat B occurred twice on
chromosome 3; both repeats were in the same orienta-
tion and were located on chromosome 3 on each side
of the breakpoint, at positions 198860847–198872158
and 197160541–197171848. These sequences were 98%
homologous, and both were 11 kb in length (fig. 2C).
In summary, there is evidence of the presence of re-
gion-specific LCRs within the genomic sequence at each
end of the microdeletion. It is likely that the formation
of the similarly sized de novo microdeletions identified
in the six patients was facilitated by these repeats and
probably arose by nonallelic homologous recombination
between LCRs on each side of the breakpoint, resulting
in a single copy of the LCR and a genomic deletion be-
tween them. Alternatively, the presence of LCRs on each
side of the deletion may not be directly involved in the
deletion, per se, but they may act to predispose the ge-
nome to form a deletion. Both disease-causing mecha-
nisms are now well recognized, although the presence of
LCRs on each side of the deletion suggests that the former
mechanism is more likely (Osborne et al. 2001; Shaw and
Lupski 2004).
This analysis of six patients with an interstitial micro-
deletion of 3q29 is the first collation of cases to delineate
3q29 microdeletion syndrome. The clinical features of a
patient from a previous report have been included for
comparison, but samples from this patient were not avail-
able to establish the exact deletion breakpoints, and the
family has been lost to clinical follow-up (E. Rossi, per-
sonal communication). The molecular deletion bound-
aries detected in the patients are strikingly similar, yet
there is considerable clinical variability in the phenotype,
with mild-to-moderate mental retardation being the only
common and consistent feature. In addition, slightly dys-
morphic facial features are similar in most patients: a long
and narrow face, short philtrum, and high nasal bridge.
As additional patients are screened for microdeletion syn-
dromes on the basis of mental retardation and autism
alone, it is likely that this syndrome will become increas-
ingly well identified. Understanding the exact molecular
mechanism of disease in these patients—that is, under-
standing how the deletion of some 22 genes in this region
affects the development of an individual—is, of course,
the next challenge. At this stage, it is impossible to at-
tribute the phenotype to any one of the deleted genes, but
two genes within the deleted area—PAK2 and DLG1—
merit further interest, since both are autosomal homo-
logues of known X-linked mental retardation genes PAK3
(MIM 300142) and DLG3 (MIM 300189). Loss-of-func-
tion mutations in either PAK3 or DLG3 result in mod-
erate-to-severe mental retardation (Allen et al. 1998; Tar-
pey et al. 2004). The DLG1 protein SAP97, like SAP102
(DLG3), is a component of the postsynaptic density, and
RNAi knockdown experiments of SAP97 result in re-
duced surface expression of GRIA1 (MIM 138248) and
GRIA2 (MIM 138247) and a decrease in both AMPA
(MIM 138248) and NMDA (MIM 138251) excitatory
postsynaptic currents (Nakagawa et al. 2004). This sug-
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Figure 2 A, Genomic map of chromosome 3q, showing which clones are present (blackened) and which clones are deleted (unblackened).
All six patients have deletions of BAC clones RP11-252K11–RP11-535N19 (see text). The MLPA probe, which can be used to detect the
deletions in all six patients, is located within the BDH gene within BAC clones RP13-616I3 and RP11-535N19. The commercially available
FISH probes—Vysis 3qter probe pVYS223B (D3S3560), Cytocell 3qtel106, and CTC-196F4—are all located within BAC clone RP5-1061C18.
Unless otherwise stated, the BAC or PAC clones used were from the RP11 library. Contig NT_029928 and the size of the BAC clones within
it are approximately to scale. The three contigs, GenBank NT_029928 (2.6 Mb), GenBank NT_005535 (1.2 Mb), and GenBank NT_005612
(100 Mb), are separated by gaps of unknown length in the sequence. B, The detailed positioning of BAC clones at the proximal and distal
breakpoints. The relative position of each BAC clone was determined by identifying the presence or absence of known STS markers within the
BAC clones and the genomic sequence around the deletion boundaries. C, LCR sequences in the deletion breakpoint genomic region. The
region-specific LCRs designated “A” and “B” are shown (see text). The arrows above the bar show the orientation of the repeats; the position
of the repeats on chromosome 3 are given below the bar. From left to right on the diagram, the repeat sizes are 15 kb, 5 kb, 11 kb, 19 kb, 19
kb, and 11 kb. The BAC clones that contain the LCRs are marked below the genomic location. The diagram is not to scale.
gests that loss of PAK2 or DLG1 may have a critical role
in the development of mental retardation in these patients,
but, clearly, this hypothesis needs further investigation.
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Web Resources
Accession numbers and URLs for data presented herein are
as follows:
BACPAC Resources Center, http://bacpac.chori.org/home.htm
(for human genomic clones from the RPCI-5, -11, and -13
BAC and PAC libraries)
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for all ac-
cession numbers of BAC and PAC clones and genomic
contigs listed in table 2)
HGMP-RC Nix Session, http://www.hgmp.mrc.ac.uk/Registered
/Webapp/nix/ (for homology searching within BAC clone
sequences)
Human BLAT Search, http://www.genome.ucsc.edu/cgi-bin
/hgBlat (for homology searching within the chromosome 3
sequence)
NCBI Map Viewer, http://www.ncbi.nlm.nih.gov/mapview/
(for BLAST sequence homology search and for transcripts
and genes within the 3q29 deleted region)
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for PAK2, MFI2, DLG1, BDH,
PAK3, and DLG3)
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